Overall Survival Date From CodeBreaK 300 for KRAS G12C-Mutated mCRC 

Filippo Pietrantonio, MD, of IRCCS Istituto Nazionale dei Tumori, and Nataliya Uboha, MD, PhD, of University of Wisconsin School of Medicine and Public Health, continue their conversation with a review of the overall survival data from the phase 3 CodeBreaK 300 study.
This trial investigated sotorasib plus panitumumab versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer.